PCVX — Vaxcyte, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1649094 ·
Last close
$61.87
Market Cap
$9.21B
52W High
$63.98
52W Low
$45.30
ADV30
947,658
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -302,777,000 | -284,302,000 | 3,138,154,000 | 183,190,000 | 380,212,000 |
| Mar 2026 | 0 | — | -345,850,000 | -320,622,000 | 3,348,308,000 | 260,843,000 | 352,294,000 |
| Dec 2025 | 0 | — | -274,283,000 | -246,507,000 | 3,002,717,000 | 173,959,000 | 317,207,000 |
| Sep 2025 | 0 | — | -242,380,000 | -212,830,000 | 3,171,600,000 | 281,080,000 | 278,718,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-881,233,000
Investing CF
$150,604,000
Financing CF
$606,021,000
CapEx
$-39,835,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-7.05
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,759,871,000
Inventory
—
Receivables
—
ST Investments
$1,303,648,000
EBIT TTM
$-1,165,290,000
Pretax Income TTM
$-1,064,261,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -923,675,000 | -766,628,000 | 3,002,717,000 | 317,207,000 | — | -655,577,000 |
| Dec 2024 | 0 | -569,546,000 | -463,927,000 | 3,511,318,000 | 205,499,000 | — | -452,627,000 |
| Dec 2023 | 0 | -393,041,000 | -402,266,000 | 1,407,917,000 | 167,449,000 | — | -296,790,000 |
| Dec 2022 | 0 | -209,261,000 | -223,485,000 | 1,006,178,000 | 52,565,000 | — | -170,597,000 |
TTM Snapshot
Revenues TTM
$46,552,000
NetIncome TTM
$-195,788,000
OpCashFlow TTM
$0
Assets (Latest)
$3,511,318,000
Forward EPS
$-7.22
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $55.00 · spot: $61.87 · call volume: 1,137 · put volume: 1
Expected Move to 2026-09-18:
±$6.86
(11.09%) —
implied range
$55.01 –
$68.73
· ATM straddle on $60.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMVT | Immunovant, Inc. | $8.95B | $43.32 | — |
| TWST | Twist Bioscience Corp | $8.83B | $140.80 | — |
| QGEN | QIAGEN N.V. | $8.63B | $41.78 | — |
| KYMR | Kymera Therapeutics, Inc. | $10.07B | $121.05 | — |
| APGE | Apogee Therapeutics, Inc. | $8.38B | $134.79 | — |
News headlines (Yahoo Finance, 1h cache)
If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone
2026-08-16 19:45 · Yahoo
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-05 20:05 · Yahoo
Vaxcyte to Participate in Upcoming Investor Conferences
2026-07-08 20:05 · Yahoo
Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now
2026-07-03 13:41 · Yahoo
Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine
2026-06-22 14:14 · Yahoo
Vaxcyte (PCVX) Completes Enrollment for Phase 3 VAX-31 Clinical Trials
2026-05-29 06:40 · Yahoo
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-06 20:05 · Yahoo
ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer
2026-08-11 12:30 · Yahoo
Pneumonia Market Set to Witness Robust Growth During the Forecast Period (2026-2036), Driven by Advancing Therapeutics and Rising Disease Burden | DelveInsight
2026-06-08 14:01 · Yahoo
Vaxcyte (PCVX) Conducts Initial Dosage for VAX-A1 Phase 1 Study
2026-06-17 15:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.